Translucence Biosystems recently participated in the Alzheimer's Association International Conference® (AAIC25), where CEO Damian Wheeler presented two posters demonstrating Translucence's whole-brain 3D tissue clearing techniques and AI-powered quantification pipeline. These presentations highlighted next-generation methodologies for quantifying disease burden and mapping therapeutic biodistribution at cellular resolution across the entire brain.
The first poster, “Whole Brain Measurement of Amyloid Plaques and Neuroinflammation in AD Model Mice” (#103712), demonstrated how Translucence Biosystems uses AI-powered workflows to segment and quantify β-amyloid plaques and microglia in 5xFAD mouse models. This approach offers a comprehensive method for evaluating novel Alzheimer's Disease models and therapeutics by providing unbiased, regionalized read-outs of amyloid plaques and microglia across hundreds of brain areas. The poster detailed the application of iDISCO-based tissue clearing, light sheet imaging, and AI-powered quantification workflows to identify individual immunostained cells and objects, offering insights into plaque density and microglial activation states.
The second poster, “Brain-Wide Measurement of Antibody Therapeutic Biodistribution and Target Engagement” (#103765), shared tools and techniques for quantifying the penetration of Antibody therapeutics across the blood-brain barrier (BBB). Conventional methods for assessing drug penetration rely on 2D histology from pre-selected brain regions, potentially overlooking critical areas and leading to a biased understanding of drug biodistribution. This poster combined 3D tissue clearing techniques, light sheet imaging, and AI-powered quantification to provide an unbiased readout of therapeutic biodistribution across the entire mouse brain at cellular resolution.
These posters demonstrate that 3D tissue clearing and AI-powered quantification workflows provide more robust insights when compared to traditional 2D histology methodologies for evaluating Alzheimer's Disease pathology and therapeutic response. For more information on the applications of our technology to Alzheimer's Disease and Therapeutic Antibody Detection, visit our science page.
Miss us at the meeting and want to connect? Please reach out to info@translucencebio.com to get in touch!
Download materials
Download materials
To access materials from this article, please complete the corresponding form
Ask your question
Send us your questions and we will get back to you as soon as possible
info@translucencebio.com
